Celladon of La Jolla, CA, has rounded up $30 million of venture capital in its second round. The funding will enable Celladon to complete preclinical testing and advance MYDICAR, its product to improve calcium handling in failing hearts, toward Phase I and II clinical trials. New investors Kleiner Perkins Caufield & Byers and Domain Associates led the round.
- read this release for more information